Table 1. Sociodemographic and clinical characteristics of depressive subjects at baseline according to Val66Met genotype distribution.
| Variables | Val66Met Genotype | p-value | |
|---|---|---|---|
| Val/Val | Val/Met and Met/Met | ||
| Age (years) | 23.9±3.3 | 23.3±3.7 | 0.491 |
| Sex (%) | |||
| Male | 20 (87%) | 3 (13%) | 0.214 |
| Female | 62 (75%) | 21 (25%) | |
| Therapy abandonment | |||
| Yes | 36 (84%) | 7 (16%) | 0.291 |
| No | 46 (73%) | 17 (27%) | |
| HRSD scores baseline | 11.9±3.6 | 12.1±3.5 | 0.781 |
| HRSD scores post treatment | 5.8±4.9 | 5.7±3.3 | 0.976 |
| HRSD scores follow-up | 8.3±5.4 | 7.7±5.2 | 0.622 |
| Resilience scores baseline | 104.4±21.5 | 114.6±17.6 | 0.037 |
| Resilience scores post treatment | 123.8±25.0 | 129.1±17.6 | 0.427 |
| Resilience scores follow-up | 125.3±23.4 | 124.2±25.7 | 0.874 |
| Total | 82 | 24 | |
Data presented as mean ± standard deviation or n (%) considering the 106 patients evaluated at baseline.
HRSD = Hamilton Rating Scale for Depression.
Bold type denotes statistically significant findings (p < 0.05). The differences were evaluated by Student’s t-test or χ2, as appropriate; p-values ≤ 0.05 were considered significant for differences in sociodemographic and clinical characteristics between Val66Met genotypes.